Share This Author
Adherence to medication.
Strategies to assess and enhance medication adherence (or compliance) are reviewed, to help patients adhere to prescribed treatment regimens and avoid stigmatization.
Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia.
Elevation of ADMA is associated with impaired endothelium-dependent vasodilation and reduced urinary nitrate excretion and this abnormality is reversed by administration of L-arginine.
Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047
SimVastatin should be avoided and atorvastatin may be used with caution in persons taking RTV and SQVsgc, and pravastatin does not alter the NFV pharmacokinetics, and thus appears to be safe for concomitant use.
Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells.
- C. Washington, G. Duran, M. Man, B. Sikic, T. Blaschke
- Biology, ChemistryJournal of acquired immune deficiency syndromes…
- 1 November 1998
Squinavir, ritonavir and nelfinavir are inhibitors and possibly substrates of P-gp, and data suggest that saquinavIR has a low bioavailability, and its interaction with P- gp may be involved in limiting its absorption.
Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories.
- T. Blaschke, L. Osterberg, B. Vrijens, J. Urquhart
- MedicineAnnual review of pharmacology and toxicology
- 11 January 2012
Electronic methods for compiling drug dosing histories are now the recognized standard for quantifying adherence, the parameters of which support model-based, continuous projections of drug actions and concentrations in plasma that are confirmable by intermittent, direct measurements at single time points.
Protein binding in antiretroviral therapies.
In June 2002, a panel of experts assembled by the Forum for Collaborative HIV Research met in Washington, DC, to discuss the basic principles of protein binding and how changes in binding can impact on drug PKs and drug exposure in vivo, and the evidence that measuring unbound concentrations of ARV drugs in the plasma of patients gives more meaningful information than total drug concentration.
Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system.
- L. Zhang, W. Gorset, C. Washington, T. Blaschke, D. Kroetz, K. Giacomini
- Biology, ChemistryDrug metabolism and disposition: the biological…
- 1 March 2000
Data suggest that HIV protease inhibitors are potent inhibitors, but poor substrates, of hOCT1, which plays an important role in the cellular uptake and elimination of various xenobiotics including therapeutically important drugs.
Updated guideline to perform therapeutic drug monitoring for antiretroviral agents.
Patient compliance and drug failure in protease inhibitor monotherapy.
To the Editor. —We conducted a 2-dose study of saquinavir in which 40 human immunodeficiency virus type 1 (HIV-1)positive patients received either three or six 200-mg capsules of saquinavir (Roche…
Pharmacokinetics of rifabutin
- M. Skinner, M. Hsieh, T. Blaschke
- Medicine, BiologyAntimicrobial Agents and Chemotherapy
- 1 August 1989
The pharmacokinetics of rifabutin was investigated in 15 male patients as part of a phase I trial of the treatment of early symptomatic human immunodeficiency virus infection, suggesting possible induction of drug-metabolizing enzymes.